NasdaqGS:REGNBiotechs
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story
Regeneron Pharmaceuticals is set to present first in class Phase 3 antibody therapy data for cat and birch allergies at the 2026 AAAAI Annual Meeting.
The presentations will focus on allergen blocking therapies targeting ocular symptoms in cat and birch allergies.
Regeneron will also share new long term analyses for Dupixent in pediatric allergy and asthma.
For investors tracking NasdaqGS:REGN, these updates come as the stock trades at $803.17, with a 1 year return of 19.9% and a 5 year...